A new study finds patients with type 2 diabetes who take GLP-1 receptor agonists are 27% more likely to develop gastroesophageal reflux disease (GERD) compared to those taking other common drugs called SGLT-2 inhibitors.
2025 © All Rights Reserved. Privacy Policy